These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7936281)

  • 21. Treatment of Painless Legs and Moving Toes Syndrome Associated With Multiple System Atrophy With Levodopa.
    Araki T; Mukai T; Araki T
    Neurology; 2021 Aug; 97(9):443-444. PubMed ID: 34045268
    [No Abstract]   [Full Text] [Related]  

  • 22. Chronic neurological disease in two manganese steel workers.
    Whitlock CM; Amuso SJ; Bittenbender JB
    Am Ind Hyg Assoc J; 1966; 27(5):454-9. PubMed ID: 4961573
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease.
    Metman LV; van den Munckhof P; Klaassen AA; Blanchet P; Mouradian MM; Chase TN
    Neurology; 1997 Sep; 49(3):711-3. PubMed ID: 9305328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deanol in the treatment of levodopa-induced dyskinesias.
    Klawans HL; Topel JL; Bergen D
    Neurology; 1975 Mar; 25(3):290-3. PubMed ID: 1167639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa.
    Pahwa R; Lyons K; McGuire D; Dubinsky R; Hubble JP; Koller WC
    Neurology; 1996 Apr; 46(4):1059-62. PubMed ID: 8780091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of hyperkinetic movement disorders.
    Bressman SB; Greene PE
    Neurol Clin; 1990 Feb; 8(1):51-75. PubMed ID: 2181268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of manganese in dystonia.
    Barbeau A; Inoué N; Cloutier T
    Adv Neurol; 1976; 14():339-52. PubMed ID: 821321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bromocriptine versus placebo in levodopa treated patients with Parkinson's disease.
    Gron U
    Acta Neurol Scand; 1977 Sep; 56(3):269-73. PubMed ID: 333855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.
    Carpentier AF; Bonnet AM; Vidailhet M; Agid Y
    Neurology; 1996 Jun; 46(6):1548-51. PubMed ID: 8649546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of oral protein on the absorption of intraduodenal levodopa and motor performance.
    Frankel JP; Kempster PA; Bovingdon M; Webster R; Lees AJ; Stern GM
    J Neurol Neurosurg Psychiatry; 1989 Sep; 52(9):1063-7. PubMed ID: 2795076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A large, nationwide, longitudinal study of central nervous system diseases among Korean workers exposed to manganese.
    Yoon JH; Ahn YS
    Parkinsonism Relat Disord; 2015 Mar; 21(3):194-8. PubMed ID: 25614347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Manganese intoxication.
    Hine CH; Pasi A
    West J Med; 1975 Aug; 123(2):101-7. PubMed ID: 1179714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bromocryptine in levodopa response-losing parkinsonism. A double blind study.
    Jansen EN
    Eur Neurol; 1978; 17(2):92-9. PubMed ID: 344042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Levodopa as a single treatment of Parkinsonism. Long-term control of 24 cases with discrimination analysis].
    Borromei A; Manzini A
    Minerva Med; 1974 Nov; 65(79):4160-70. PubMed ID: 4610450
    [No Abstract]   [Full Text] [Related]  

  • 36. Four-year treatment of patients with parkinsonism using amantadine alone or with levodopa.
    Timberlake WH; Vance MA
    Ann Neurol; 1978 Feb; 3(2):119-28. PubMed ID: 350129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Dyskinetic-athetosic syndrome in a patient with prior radiculo-myelo-encephalopathy of probable viral origin. Therapeutic guidelines with levodopa and preliminary results].
    Bossi L; Nobili M; Benedetto P
    Arch Sci Med (Torino); 1979; 136(3):417-20. PubMed ID: 549546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double-blind, placebo-controlled study of levodopa therapy in Parkinson's disease.
    Muenter MD
    Neurology; 1970 Dec; 20(12):Suppl:6-13. PubMed ID: 4921587
    [No Abstract]   [Full Text] [Related]  

  • 39. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I.
    Kurth MC; Adler CH; Hilaire MS; Singer C; Waters C; LeWitt P; Chernik DA; Dorflinger EE; Yoo K
    Neurology; 1997 Jan; 48(1):81-7. PubMed ID: 9008498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies.
    Mouradian MM; Juncos JL; Fabbrini G; Chase TN
    Ann Neurol; 1987 Oct; 22(4):475-9. PubMed ID: 3435068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.